Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

Journal article

Peer reviewed

T.J. Herzog, G.E. Richardson, B.J. Monk, B.Y. Karlan, C. Marth, L. Navale, D.J. Warner and A.M. Oza

Gynecologic oncology, Vol.133, pp.41-42

06/2014

Metrics

1 Record Views

Title: Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer
Creators: T.J. Herzog - Columbia University
G.E. Richardson - Cabrini Hospital
B.J. Monk - University of Arizona
B.Y. Karlan - Cedars-Sinai Medical Center
C. Marth - Innsbruck Medical University
L. Navale - Amgen
D.J. Warner - The Thousand
A.M. Oza - Princess Margaret Cancer Centre
Publication Details: Gynecologic oncology, Vol.133, pp.41-42
Publisher: Elsevier Inc
Identifiers: 991005969002702656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article